Based on the observations that RNR was one of the afatinib-targeted proteins, we then further examined whether there was a combination effect of afatinib with gemcitabine (a well-known inhibitor of RNR) on the viability, RRM1 and RRM2 protein levels of human lung cancer cells. Here, RRM2 is linked to lung carcinoma.